Advancing Modern Precision Oncology
The ImmunoID NeXT Platform™ is designed specifically to enable the development of more efficacious cancer immunotherapies. While the success of checkpoint blockade has been hugely promising, the majority of patients who are administered these therapeutics demonstrate no response at all, with some even experiencing disease hyperprogression post-treatment (Kato et al., 2017).
It’s increasingly apparent that predicting response to immunotherapies — and developing new ones — requires a more comprehensive approach to tumor immunogenomics. With highly-sensitive, exome-scale DNA and RNA analytics, ImmunoID NeXT™ addresses this problem; providing a multidimensional view of a tumor and its tumor microenvironment (TME) from a single sample.
Figure 1: The ImmunoID NeXT Platform represents an end-to-end solution for immuno-oncology and all precision oncology applications. It combines the pioneering NeXT assay, sophisticated analytical engines, and quality support to provide researchers with the comprehensive immunogenomic data they need to drive their programs.
Specifically built for immuno-oncology and all precision oncology applications, the ImmunoID NeXT Platform can be used to investigate key areas of tumor biology; from elucidating mechanisms of tumor escape and detecting neoantigens, to identifying novel biomarker signatures and characterizing the immune repertoire. With these extensive capabilities, ImmunoID NeXT effectively consolidates multiple biomarker assays into one.
The unique, innovative design of the assay and analytical algorithms enables – for the first time from a single platform – the delivery of critical tumor and microenvironment-related information such as:
- T-cell receptor (TCR) repertoire composition
- Neoantigen detection and neoantigen load
- Human leukocyte antigens (HLA) typing
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI) characterization
- Tumor escape mechanisms
- Immune response
- Oncoviral detection
ImmunoID NeXT analytics leverage the accurate, raw data to evaluate the status of the most relevant oncology biomarkers, as have been identified and investigated in the literature.
RepertoireID enables the analysis of the TCRβ clonotypes in patients’ tumor FFPE (as well as fresh frozen) samples. The ultra-deep, TCR-specific RNA sequencing data derived from the NeXT assay is processed by our TCR Analytics Engine, and a report is generated providing key metrics such as clonality; CDR3 nucleotide and amino acid sequences; clonotype quantitation, distribution, and frequency; V, D, and J gene segments usage and overlap; and CDR3 nucleotide sequence length. These deliverables enable researchers to investigate the TCR repertoire’s potential as a predictive biomarker of response to immunotherapies and combination therapies.
ImmunoID NeXT is the first commercial platform that enables the comprehensive characterization of the immune repertoire using data derived from an augmented, exome-scale platform, designed specifically to explore multidimensional oncology biomarkers.
ImmunogenomicsID provides an overview of TME-related biomarkers and critical genes that are involved in, or highly impact key oncology functional groups including antigen presenting machinery (APM), DNA repair and replication, immune checkpoint modulation, tumor associated antigens (TAAs), adaptive and innate immune response, cytokines and chemokines, and cytotoxicity.
Utilizing an industry-leading algorithm, ImmunogenomicsID also provides a characterization of MSI within a tumor sample, highlighting the stability status of five canonical loci, as well as the proportion of all microsatellite loci that are found to be instable.
Deep and uniform coverage (of both DNA and RNA) is critical for both comprehensive neoantigen identification and the accurate assessment of neoantigen load. ImmunoID NeXT ensures highly-sensitive variant detection via both the depth of sequencing (~300X mean coverage) and the augmented coverage of difficult-to-sequence regions across the entire >20,000 gene footprint. Combined, these features reduce the chances of neoantigen-producing variants (SNVs, indels, and fusions) going undetected.
NeoantigenID utilizes the tumor and matched normal ImmunoID NeXT configuration to accurately differentiate between somatic and germline mutations and to generate analytics for the identification of potentially immunogenic neoantigens, incorporating information such as HLA typing, MHC-binding prediction (for Class I and Class II), similarity-to-self, similarity-to-known antigens, and immunogenicity.
In addition to the identification of putative neoantigens for personalized therapeutic development, NeoantigenID also provides an evaluation of the mutational landscape of the tumor, delivering both the neoantigen load and TMB for biomarker discovery applications.
Want to learn more about the ImmunoID NeXT Platform?